Illegal drug use remains a significant public health challenge across the European Union, with cannabis and cocaine leading the statistics.
According to a joint report from the European Commission and the Organisation for Economic Co-operation and Development (OECD), nearly one in three Europeans has tried illegal drugs at some point in their lives.
While cannabis and cocaine remain the most commonly used substances, emerging threats from synthetic drugs and opioids are alarming health experts.
The Prevalence of Cannabis and Cocaine Use
Among young adults in the EU, cannabis usage rates are particularly striking. The report reveals that 15% of individuals aged 15 to 34 have used cannabis in the past year.
Among adults, the highest rates of cannabis use are observed in the Czech Republic, Italy, France, and Spain, while Malta, Turkey, and Hungary report the lowest levels.
Cocaine use, though less widespread than cannabis, is still concerning. Approximately 2.5% of young adults in the EU report using cocaine annually.
The Netherlands, Spain, and Ireland lead in cocaine use, whereas Turkey, Portugal, Poland, and Hungary record the lowest prevalence.
Notably, the strictness of a country’s drug laws does not appear to correlate strongly with drug availability or usage rates.
“The major penalties impact only the people who use the substance once or fewer times in a year, so not the real [heavy] users,” said Sabrina Molinaro, an epidemiologist and research director at the National Research Council of Italy.
Generational Trends in Drug Habits
Molinaro, who coordinates the European School Survey Project on Alcohol and Other Drugs, has tracked drug use among 16-year-olds in Europe since the 1990s.
She notes that generational trends in drug habits are remarkably consistent over time. Patterns observed among teenagers tend to manifest in adult-level data in subsequent years.
One notable trend is the narrowing gender gap in cannabis use among teenagers.
Historically, teenage boys were more likely than girls to use cannabis, but recent years have seen this gap close. In some countries, teenage girls have even surpassed boys in cannabis use.
The Rise of Synthetic Drugs and Other Emerging Threats
While cannabis and cocaine dominate the drug landscape in the EU, other substances are rapidly becoming public health concerns.
Synthetic drugs, including lab-made cannabinoids and stimulants, are of particular worry due to their unpredictable composition and high potency.
“They are so dangerous [because] you don’t know what you are taking,” Molinaro explained. “The drugs are often made in low-quality labs with the potential for pollution.”
According to the EU Drug Agency (EUDA), hundreds of synthetic drug labs were dismantled across the EU in 2022.
The agency’s early warning system identified seven new synthetic opioid substances in 2023 alone. These opioids are highly potent and pose severe health risks to the adult population.
Psychedelic substances, MDMA (commonly known as ecstasy), heroin, and other opioids continue to present significant risks.
Europe’s increasing drug diversity complicates the task of national authorities to identify, regulate, and combat emerging substances.
Health Risks Associated with Drug Use
Regular drug use carries numerous health risks, including cardiovascular diseases, mental health disorders, accidents, and infectious diseases such as HIV, particularly in the context of injectable drugs.
Young adults are especially vulnerable to the adverse effects of drug use, with long-term implications for their physical and mental health.
Synthetic drugs amplify these risks due to their unpredictable chemical compositions. Many synthetic drugs are produced in unregulated environments, leading to contamination and heightened toxicity.
Users often have little to no knowledge of what they are consuming, increasing the likelihood of overdoses and adverse reactions.
Addressing the Public Health Challenge
Despite significant efforts to curb drug use, the availability of illegal substances remains a persistent issue.
Experts argue that stricter penalties alone are insufficient to address the problem. Instead, comprehensive strategies that include education, harm reduction, and early intervention are essential.
Consumption centers, such as the one recently opened in Brussels, aim to reduce the health risks associated with drug use while keeping drugs off the streets.
These centers provide a safer environment for drug users, reducing the spread of infectious diseases and offering access to healthcare and rehabilitation services.
The Role of Policy and Education
To combat the growing drug problem, EU countries must invest in education and awareness campaigns targeting young people.
By addressing the root causes of drug use and equipping individuals with the knowledge and resources to make informed choices, policymakers can work towards reducing demand.
Additionally, the rapid proliferation of synthetic drugs requires a coordinated international response.
Improved collaboration between EU member states, enhanced surveillance systems, and quicker regulatory actions are crucial to staying ahead of traffickers and preventing new substances from reaching the market.
Conclusion
The landscape of drug use in the EU is evolving, with cannabis and cocaine remaining prevalent but synthetic drugs and other substances posing new challenges.
Addressing this multifaceted issue requires a balanced approach that combines enforcement with education, harm reduction, and healthcare access.
As Europe continues to grapple with these issues, it is clear that proactive and innovative strategies will be essential in protecting public health and mitigating the impact of drug use.
This article was created using automation technology and was thoroughly edited and fact-checked by one of our editorial staff members